Neomidantan (Amantadine Hydrochloride)

Amantadine blocks the M2 ion channel of influenza A virus, preventing viral uncoating and replication. In the brain it antagonizes NMDA receptors and promotes dopamine release, which helps improve motor function in Parkinsonian states and counteracts extrapyramidal side effects.

The dosage of Neomidantan is individualized by the prescribing clinician based on the specific indication, patient age, renal function, and other clinical factors. The prescriber determines the appropriate strength, frequency, and duration of therapy.

Safety data for amantadine in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To request Neomidantan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

For influenza A, the most common alternative is oseltamivir, a neuraminidase inhibitor that works by blocking viral release rather than entry. In Parkinson's disease, levodopa remains the first‑line therapy; amantadine is typically added for its modest dopaminergic effect and to address dyskinesia, offering a different side‑effect profile.

Neomidantan should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Neomidantan is administered orally. The tablet (or other oral dosage form) should be swallowed whole with a glass of water, unless the prescribing information advises otherwise. It is taken with or without food as directed by the healthcare provider.

Serious adverse reactions include livedo reticularis, severe skin reactions such as Stevens‑Johnson syndrome, hallucinations or psychosis, cardiac arrhythmias, and anaphylaxis. Patients should seek immediate medical attention if they experience any of these symptoms.

Neomidantan is contraindicated in individuals with known hypersensitivity to amantadine or any component of the formulation, and it should be avoided in patients with severe renal impairment unless dose adjustments are made. Caution is also advised for those with uncontrolled cardiac arrhythmias or a history of severe psychiatric disorders.